David Ho (L) and Yaoxing Huang (RenBio)

HIV re­searcher David Ho has a new line of at­tack on SARS-CoV-2, and his fledg­ling start­up is gun­ning for the clin­ic

The famed AIDS re­searcher David Ho start­ed off the Covid-19 pan­dem­ic work­ing to de­vel­op an an­ti­body against the SARS-CoV-2 virus, but now he’s be­hind a new biotech that’s tak­ing a slight­ly dif­fer­ent ap­proach to fight the dis­ease.

Ho is a co-founder of Ren­Bio, which pulled in its first fundraise Thurs­day morn­ing with a $24 mil­lion Se­ries A, the com­pa­ny an­nounced. The biotech is pour­ing its first ef­forts in­to a bis­pe­cif­ic an­ti­body tar­get­ing two sites on the SARS-CoV-2 spike pro­tein, and is tout­ing ac­tiv­i­ty against sev­er­al Covid-19 vari­ants of con­cern in­clud­ing strains orig­i­nat­ing from the UK, South Africa and Brazil, among oth­ers.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.